{"id":39733,"date":"2023-11-06T06:50:13","date_gmt":"2023-11-06T05:50:13","guid":{"rendered":"https:\/\/www.infokuryr.cz\/n\/?p=39733"},"modified":"2023-11-06T06:50:13","modified_gmt":"2023-11-06T05:50:13","slug":"farmaceuticke-firmy-cili-pilulky-na-hubnuti-pro-6lete-deti-navzdory-znamym-zdravotnim-rizikum","status":"publish","type":"post","link":"https:\/\/www.infokuryr.cz\/n\/2023\/11\/06\/farmaceuticke-firmy-cili-pilulky-na-hubnuti-pro-6lete-deti-navzdory-znamym-zdravotnim-rizikum\/","title":{"rendered":"Farmaceutick\u00e9 firmy c\u00edl\u00ed pilulky na hubnut\u00ed pro 6let\u00e9 d\u011bti, navzdory zn\u00e1m\u00fdm zdravotn\u00edm rizik\u016fm"},"content":{"rendered":"
<\/div>\n

Velk\u00e9 farmaceutick\u00e9 firmy se chystaj\u00ed spustit klinick\u00e9 testy l\u00e9k\u016f proti obezit\u011b u d\u011bt\u00ed ve v\u011bku od \u0161esti let, a to i p\u0159es obavy, \u017ee tyto l\u00e9ky mohou zp\u016fsobit paral\u00fdzu \u017ealudku \u010di sebevra\u017eedn\u00e9 my\u0161lenky.<\/span><\/p>\n

Farmaceuti\u010dt\u00ed giganti ozn\u00e1mili, \u017ee pl\u00e1nuj\u00ed naverbovat d\u011bti, aby otestovali sv\u00e9 popul\u00e1rn\u00ed l\u00e9ky na hubnut\u00ed, z nich\u017e v\u0161echny maj\u00ed rizika pro fyzick\u00e9 i du\u0161evn\u00ed zdrav\u00ed.<\/span><\/p>\n

Spole\u010dnost Novo Nordisk, v\u00fdrobce l\u00e9k\u016f Ozempic a Wegovy, a spole\u010dnost Eli Lilly, v\u00fdrobce l\u00e9ku Mounjaro, ji\u017e maj\u00ed sv\u00e9 l\u00e9ky schv\u00e1len\u00e9 v USA a Evropsk\u00e9 unii pro lidi ve v\u011bku 12 a v\u00edce let.\u00a0Nyn\u00ed cht\u011bj\u00ed j\u00edt do ni\u017e\u0161\u00edch v\u011bkov\u00fdch kategori\u00ed.<\/span><\/p>\n

Podle zpr\u00e1v je spole\u010dnost Novo Nordisk ji\u017e \u00fadajn\u011b ve t\u0159et\u00ed f\u00e1zi zkou\u0161ek s d\u011btmi ve v\u011bku 6 a\u017e 12 let, na kter\u00fdch testuje sv\u016fj produkt Saxenda.\u00a0Eli Lilly za\u010dala s n\u00e1borem d\u011bt\u00ed pro klinick\u00e9 zkou\u0161ky minul\u00fd t\u00fdden.<\/span><\/p>\n

Mluv\u010d\u00ed Eli Lilly pro Bloomberg \u0159ekl:<\/span><\/p>\n

\u201eUr\u010dit\u011b jsme odhodl\u00e1ni inovovat v tomto prostoru, kter\u00fd oslov\u00ed v\u0161echny segmenty populace, kter\u00fdch se to t\u00fdk\u00e1.\u201c<\/span><\/em><\/p>\n

Port\u00e1l\u00a0<\/span>The Defender<\/span><\/a>\u00a0uv\u00e1d\u00ed:<\/span><\/p>\n

V koment\u00e1\u0159i ohledn\u011b marketingov\u00fdch pl\u00e1n\u016f pro l\u00e9ky Ozempic a Mounjaro ur\u010den\u00e9 mlad\u0161\u00edm d\u011btem, nutri\u010dn\u00ed specialistka Carrie Lupoli pro NewsNation \u0159ekla:<\/span><\/p>\n

\u201eJe pro m\u011b d\u011bsiv\u00e9, \u017ee jdeme touto cestou m\u00edsto toho, abychom pracovali hlavn\u011b na p\u0159\u00ed\u010din\u00e1ch obezity d\u011bt\u00ed, proto\u017ee v\u00edme, \u017ee p\u0159ib\u00edr\u00e1n\u00ed je p\u0159\u00edznakem zdrav\u00ed a hormon\u016f.<\/span><\/em><\/p>\n

Pilulky na hubnut\u00ed n\u00e1m nepomohou st\u00e1t se zdrav\u011bj\u0161\u00edm n\u00e1rodem.\u00a0Jedin\u00e9, \u010deho se t\u00edm dos\u00e1hne, je utvrzen\u00ed se v my\u0161lence, \u017ee je akceptovateln\u00e9 hubnout jak\u00fdmkoli zp\u016fsobem.\u201c<\/span><\/em><\/p>\n

Semaglutid, aktivn\u00ed slo\u017eka v l\u00e9c\u00edch Ozempic a Wegovy, liraglutid, aktivn\u00ed slo\u017eka v p\u0159\u00edpravku Saxende a tirzepatid, aktivn\u00ed slo\u017eka v p\u0159\u00edpravku Mounjaro, v\u0161echny pat\u0159\u00ed do t\u0159\u00eddy l\u00e9k\u016f naz\u00fdvan\u00fdch inkretinov\u00e1 mimetika.\u00a0Jsou navr\u017eeny tak, aby napodobovaly t\u011blu p\u0159irozen\u00fd hormon uvol\u0148uj\u00edc\u00ed inzul\u00edn, kter\u00fd lidem s diabetem 2. typu nebo obezitou bu\u010f chyb\u00ed, nebo jej maj\u00ed nedostatek.<\/span><\/p>\n

V\u0161echny t\u0159i l\u00e9\u010diva funguj\u00ed jako agonist\u00e9 receptoru glukagonu podobn\u00e9ho peptidu-1 (GLP-1).\u00a0Hormon GLP-1 pom\u00e1h\u00e1 regulovat hladinu cukru v krvi t\u00edm, \u017ee p\u0159inut\u00ed slinivku b\u0159i\u0161n\u00ed uvol\u0148ovat inzul\u00edn, kter\u00fd pom\u00e1h\u00e1 t\u011blu zpracovat gluk\u00f3zu (cukr) na energii.<\/span><\/p>\n

L\u00e9ky se v\u00e1\u017e\u00ed na stejn\u00e9 receptory jako GLP-1, co\u017e zp\u016fsobuje, \u017ee t\u011blo uvol\u0148uje b\u011bhem konzumace j\u00eddla v\u00edce inzul\u00ednu a pokud nejste rezistentn\u00ed na inzul\u00edn, tak sni\u017euje hladinu cukru v krvi.<\/span><\/p>\n

Tirzepatid v p\u0159\u00edpravku Mounjaro, kter\u00fd se ozna\u010duje jako \u201edu\u00e1ln\u00ed ko-agonista\u201c, se tak\u00e9 zam\u011b\u0159uje na receptor inzul\u00ednotropn\u00edho polypeptidu z\u00e1visl\u00e9ho na gluk\u00f3ze (GIP), kter\u00fd potenci\u00e1ln\u011b poskytuje siln\u011bj\u0161\u00ed inzul\u00ednovou odpov\u011b\u010f s v\u011bt\u0161\u00edm potla\u010den\u00edm glukagonu a zv\u00fd\u0161en\u00fdmi \u00fa\u010dinky na sn\u00ed\u017een\u00ed hmotnosti.<\/span><\/p>\n

\n
\n

\"\"<\/a><\/p>\n<\/div>\n<\/div>\n

Dr.\u00a0Ibiye Owei, odborn\u00fd asistent ze Zdravotnick\u00e9ho centra p\u0159i Texask\u00e9 technick\u00e9 univerzity v El Paso, \u0159ekl port\u00e1lu Healthline, \u017ee semaglutid \u201efunguje tak, \u017ee se lid\u00e9 c\u00edt\u00ed sp\u00ed\u0161e syt\u00ed d\u00edky tomu, \u017ee se zpomaluje vyprazd\u0148ov\u00e1n\u00ed \u017ealudku, tak\u017ee vznik\u00e1 pocit sytosti\u201c.<\/span><\/p>\n

L\u00e9ky tak\u00e9 potla\u010duj\u00ed chu\u0165 k j\u00eddlu.\u00a0P\u0159esto\u017ee mechanismy nejsou pln\u011b pochopeny, v\u011bdci poukazuj\u00ed na receptory GLP-1 v r\u016fzn\u00fdch oblastech mozku, kter\u00e9 se pod\u00edlej\u00ed na regulaci chuti k j\u00eddlu a pocitu uspokojen\u00ed \u2013 zejm\u00e9na p\u0159i potla\u010dov\u00e1n\u00ed dopaminov\u00e9 signalizace, kter\u00e1 ovliv\u0148uje vztah mezi j\u00eddlem a uspokojen\u00edm.<\/span><\/p>\n

Uk\u00e1zalo se, \u017ee tyto l\u00e9ky maj\u00ed i dal\u0161\u00ed zdrav\u00ed prosp\u011b\u0161n\u00e9 \u00fa\u010dinky, jako je sn\u00ed\u017een\u00ed\u00a0<\/span>krevn\u00edho tlaku<\/span><\/a>\u00a0, zlep\u0161en\u00ed pr\u016ftoku krve do srdce, sn\u00ed\u017een\u00ed rizika srde\u010dn\u00edho infarktu a mozkov\u00e9 p\u0159\u00edhody a ochrana bun\u011bk slinivky b\u0159i\u0161n\u00ed.<\/span><\/p>\n

Americk\u00e1 Agentura pro potraviny a l\u00e9\u010diva (FDA) v roce 2020 schv\u00e1lila l\u00e9k Ozempic pro sn\u00ed\u017een\u00ed rizika infarktu a mrtvice.<\/span><\/p>\n

L\u00e9ky se obvykle dod\u00e1vaj\u00ed v tekut\u00e9 form\u011b a pod\u00e1vaj\u00ed se samostatn\u011b t\u00fddn\u011b prost\u0159ednictv\u00edm injekc\u00ed do b\u0159icha, vn\u011bj\u0161\u00edch stehen, horn\u00ed \u010d\u00e1sti h\u00fd\u017ed\u00ed nebo zadn\u00ed \u010d\u00e1sti pa\u017e\u00ed.<\/span><\/p>\n

L\u00e9ky na hubnut\u00ed maj\u00ed tak\u00e9 dlouh\u00fd seznam ne\u017e\u00e1douc\u00edch \u00fa\u010dink\u016f<\/span><\/h2>\n

FDA minul\u00fd m\u011bs\u00edc aktualizovala varovn\u00e9 \u0161t\u00edtky se seznamem ne\u017e\u00e1douc\u00edch \u00fa\u010dink\u016f pro l\u00e1tku semaglutid (pou\u017e\u00edvanou v l\u00e9c\u00edch Ozempic, Wegovy a Rybelsus), aby zahrnovaly riziko rozvoje ileusu \u2013 st\u0159evn\u00ed obstrukce, kter\u00e1 m\u016f\u017ee b\u00fdt \u017eivot ohro\u017euj\u00edc\u00ed.<\/span><\/p>\n

FDA uv\u00e1d\u00ed dal\u0161\u00ed ne\u017e\u00e1douc\u00ed \u00fa\u010dinky t\u011bchto l\u00e9k\u016f, v\u010detn\u011b pankreatitidy, akutn\u00edho po\u0161kozen\u00ed ledvin, akutn\u00edho onemocn\u011bn\u00ed \u017elu\u010dn\u00edku, komplikac\u00ed diabetick\u00e9 retinopatie, rizika rakoviny C-bun\u011bk \u0161t\u00edtn\u00e9 \u017el\u00e1zy a hypoglyk\u00e9mie p\u0159i pou\u017eit\u00ed spolu s inzul\u00ednem nebo l\u00e9ky, kter\u00e9 zvy\u0161uj\u00ed sekreci inzul\u00ednu.<\/span><\/p>\n

P\u0159ibli\u017en\u011b jedna t\u0159etina \u00fa\u010dastn\u00edk\u016f klinick\u00fdch studi\u00ed uv\u00e1d\u011bla gastrointestin\u00e1ln\u00ed (GI) probl\u00e9my, v\u010detn\u011b nevolnosti, zvracen\u00ed, pr\u016fjmu, bolesti b\u0159icha a z\u00e1cpy.\u00a0M\u00e9n\u011b \u010dast\u00e9 GI probl\u00e9my zahrnovaly dyspepsii,\u00a0<\/span>plynatost<\/span><\/a>\u00a0, gastroezofage\u00e1ln\u00ed reflux, gastritidu a eruktaci (\u0159\u00edh\u00e1n\u00ed).<\/span><\/p>\n

Studie na b\u0159ez\u00edch zv\u00ed\u0159atech uk\u00e1zaly abnorm\u00e1ln\u00ed v\u00fdvoj plodu, brzk\u00e9 ukon\u010den\u00ed t\u011bhotenstv\u00ed a men\u0161\u00ed vzr\u016fst potomstva.<\/span><\/p>\n

V\u00edce ne\u017e 500 hl\u00e1\u0161en\u00ed o \u00fazkosti, depresi a sebevra\u017eedn\u00fdch my\u0161lenk\u00e1ch<\/span><\/h2>\n

Toto l\u00e9to za\u010daly evropsk\u00e9 regula\u010dn\u00ed org\u00e1ny prov\u011b\u0159ovat l\u00e9ky Ozempic a Saxendu za to, \u017ee u n\u011bkter\u00fdch u\u017eivatel\u016f \u00fadajn\u011b vyvol\u00e1valy sebevra\u017eedn\u00e9 my\u0161lenky.<\/span><\/p>\n

Deprese a sebevra\u017eedn\u00e9 my\u0161lenky jsou uvedeny jako mo\u017en\u00e9 vedlej\u0161\u00ed \u00fa\u010dinky p\u0159\u00edpravku Wegovy, kter\u00fd obsahuje vy\u0161\u0161\u00ed d\u00e1vku semaglutidu ne\u017e jeho sestersk\u00fd l\u00e9k Ozempic, kter\u00fd tyto \u00fa\u010dinky neuv\u00e1d\u00ed.<\/span><\/p>\n

Podle farmaceutick\u00e9ho korespondenta NPR Sydneyho Lupkina syst\u00e9m hl\u00e1\u0161en\u00ed ne\u017e\u00e1douc\u00edch ud\u00e1lost\u00ed FDA (FAERS) zaznamenal t\u00e9m\u011b\u0159 500 hl\u00e1\u0161en\u00ed o \u00fazkosti, depresi nebo sebevra\u017eedn\u00fdch my\u0161lenk\u00e1ch od lid\u00ed u\u017e\u00edvaj\u00edc\u00edch semaglutidov\u00e9 l\u00e9ky \u2013 v\u010detn\u011b Ozempicu.<\/span><\/p>\n

P\u011bt z pacient\u016f, kte\u0159\u00ed m\u011bli sebevra\u017eedn\u00e9 my\u0161lenky, pozd\u011bji zem\u0159elo.<\/span><\/p>\n

FDA minul\u00fd m\u011bs\u00edc pro NPR \u0159ekla, \u017ee nesleduje regula\u010dn\u00ed org\u00e1ny EU p\u0159i prov\u011b\u0159ov\u00e1n\u00ed zpr\u00e1v o sebevra\u017eedn\u00fdch my\u0161lenk\u00e1ch, ale situaci monitoruje a tvrd\u00ed, \u017ee nad\u00e1le \u201ezast\u00e1v\u00e1 n\u00e1zor, \u017ee p\u0159\u00ednosy t\u011bchto l\u00e9k\u016f p\u0159eva\u017euj\u00ed nad jejich riziky\u201c.<\/span><\/p>\n

Autor: Niamh Harrisov\u00e1, Zdroj:\u00a0\u00a0<\/span>thepeoplesvoice.tv<\/span><\/a>\u00a0<\/span><\/p>\n

 <\/p>\n

 <\/p>\n","protected":false},"excerpt":{"rendered":"

Velk\u00e9 farmaceutick\u00e9 firmy se chystaj\u00ed spustit klinick\u00e9 testy l\u00e9k\u016f proti obezit\u011b u d\u011bt\u00ed ve v\u011bku…<\/p>\n","protected":false},"author":2,"featured_media":39734,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":[],"categories":[7],"tags":[245,6220,358,6219],"_links":{"self":[{"href":"https:\/\/www.infokuryr.cz\/n\/wp-json\/wp\/v2\/posts\/39733"}],"collection":[{"href":"https:\/\/www.infokuryr.cz\/n\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.infokuryr.cz\/n\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.infokuryr.cz\/n\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.infokuryr.cz\/n\/wp-json\/wp\/v2\/comments?post=39733"}],"version-history":[{"count":0,"href":"https:\/\/www.infokuryr.cz\/n\/wp-json\/wp\/v2\/posts\/39733\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.infokuryr.cz\/n\/wp-json\/wp\/v2\/media\/39734"}],"wp:attachment":[{"href":"https:\/\/www.infokuryr.cz\/n\/wp-json\/wp\/v2\/media?parent=39733"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.infokuryr.cz\/n\/wp-json\/wp\/v2\/categories?post=39733"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.infokuryr.cz\/n\/wp-json\/wp\/v2\/tags?post=39733"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}